Dermapharm Holding SE Logo

Dermapharm Holding SE

Manufactures patent-free branded pharmaceuticals & healthcare products for niche markets.

DMP | F

Overview

Corporate Details

ISIN(s):
DE000A2GS5D8
LEI:
5299009F0KNZINQQQK37
Country:
Germany
Address:
Lil-Dagover-Ring 7, 82031 Grünwald
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dermapharm Holding SE is a manufacturer of patent-free branded pharmaceuticals and other healthcare products. Established in 1991, the company operates an integrated business model encompassing in-house research, development, production, and distribution. Its activities are primarily structured into two segments: "Branded pharmaceuticals and other healthcare products" and "Parallel import business." The company focuses on profitable, niche markets and implements a growth strategy that combines organic development with targeted acquisitions to expand its product portfolio and international footprint. Key assets include in-house R&D competence, a pipeline of development projects, and over 1,300 marketing authorizations for products such as over-the-counter medicines and herbal supplements.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:30
Earnings Release
Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong…
English 24.7 KB
2025-11-13 00:00
Regulatory News Service
Q3 statement / Q3 financial report 2025
English 350.5 KB
2025-11-05 13:48
Report Publication Announcement
English 4.0 KB
2025-11-03 11:45
Director's Dealing
Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy
English 6.3 KB
2025-08-26 07:30
Earnings Release
Dermapharm confirms stable business development in H1 2025 and records EBITDA g…
English 25.4 KB
2025-08-26 00:00
Interim Report
Half-yearly financial report 2025
English 1.5 MB
2025-08-18 09:26
Report Publication Announcement
English 4.0 KB
2025-08-12 07:30
Earnings Release
Dermapharm Holding SE remains on projected growth trajectory in Q2 2025
English 15.1 KB
2025-07-04 16:18
Director's Dealing
Dermapharm Holding SE: Wilhelm Beier, buy
English 5.8 KB
2025-07-01 12:30
Declaration of Voting Results & Voting Rights Announcements
German 12.3 KB
2025-06-27 14:40
Declaration of Voting Results & Voting Rights Announcements
English 12.0 KB
2025-06-26 17:43
Post-Annual General Meeting Information
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of…
English 10.9 KB
2025-06-24 16:46
Director's Dealing
Dermapharm Holding SE: Dr. Andreas Eberhorn, buy
English 5.8 KB
2025-06-05 12:29
Director's Dealing
Dermapharm Holding SE: Anja Schorn, buy
English 6.2 KB
2025-06-04 11:19
Director's Dealing
Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy
English 6.9 KB

Automate Your Workflow. Get a real-time feed of all Dermapharm Holding SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dermapharm Holding SE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dermapharm Holding SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-30 Themis Beteiligungs-Aktiengesellschaft Close relation Buy None 54,530,000.00 EUR
2024-12-30 Beier, Wilhelm Supervisory board Buy None 3,895,000.00 EUR
2024-11-15 Themis Beteiligungs-Aktiengesellschaft Close relation Buy None 6,464,000.00 EUR
2024-11-11 Feldmeier, Dr. Hans-Georg Board Buy None 95,185.00 EUR
2024-11-05 Dreibholz, Christof Board Buy None 27,720.00 EUR
2024-10-23 Lanz, Susanne Gertrud Pia Close relation Buy None 19,704.55 EUR
2024-08-29 Themis Beteiligungs-Aktiengesellschaft Close relation Buy None 29,954,600.00 EUR
2024-06-11 Lanz, Susanne Gertrud Pia Close relation Buy None 101,778.57 EUR
2024-05-22 Themis Beteiligungs-Aktiengesellschaft Close relation Buy None 8,577,500.00 EUR
2023-06-27 Feldmeier, Dr. Hans-Georg Board Buy None 99,902.36 EUR

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.